GLP-3.io — Retatrutide News, Research & Complete Guide 2026

Your complete resource for Retatrutide (LY3437943), the world's first triple-agonist medication targeting GLP-1, GIP, and Glucagon receptors. Latest clinical trials, FDA updates, and educational guides.

Latest Articles

Is 'Bemlayo' the Official Name for Retatrutide? Analyzing Eli Lilly's Trademark Filings
The Retatrutide Paradox: Trial Dropouts Due to Excessive Weight Loss
The Triple-Digit Surge: Why Lilly's Dual-Action Therapy is Dominating
The GLP-3 Anabolic Muscle Protocol
UAB GLP-1 Revolution: What Researchers Are Discovering
The Ozempic Effect: Sugar Industry's Historic Decline
Tirzepatide and Diabetic Eye Disease Protection
Ozempic Price Drop: Patent Expiration & the Retatrutide Era
Retatrutide and Fatty Liver (MASH) Reversal
TRIUMPH-9 Clinical Trial Recruitment
Hollywood's Next Secret: From Ozempic to the 'Godzilla Drug'
Retatrutide Reddit: Real User Insights
Retatrutide Release Date 2026
Retatrutide vs Mounjaro Comparison
Retatrutide Side Effects & Safety Guide

Guides

Retatrutide Titration Protocol
Best Electrolytes for Retatrutide Dehydration

About Retatrutide

Retatrutide (LY3437943) is an investigational triple-agonist developed by Eli Lilly targeting GLP-1, GIP, and Glucagon receptors simultaneously. In Phase 3 TRIUMPH clinical trials, it demonstrated up to 28.7% average weight loss — the most potent result ever recorded for a weight management medication. The drug is expected to launch under the brand name Bemlayo in late 2027 or 2028.

Compare Drugs

Compare Retatrutide vs Mounjaro vs Ozempic vs Zepbound — side-by-side mechanism, efficacy, and safety data.